Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo

Trial Profile

Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2018

At a glance

  • Drugs Ospemifene (Primary)
  • Indications Atrophic vaginitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Shionogi
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 18 May 2012 Extension study results assessing endometrial safety presented at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
    • 01 Jun 2010 Primary endpont results (n=826) published in Menopause
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top